Clinical Genomics recently closed a $15 million series A financing round.
Here are four points:
1. The funds will be used to advance commercialization of the company's two-gene blood test for post-surgical monitoring of colorectal cancer recurrence.
2. The blood test aims to detect tumor-specific methylated DNA biomarkers that leak from active lesions into the circulatory system.
3. The financing is being led by OneVentures, a venture capital firm.
4. Paul Kelly, MD, partner and managing director of OneVentures, will join Clinical Genomics' board of directors in connection with the financing.